A recent data analysis has indicated higher than expected recurrence rates and deaths for women with hormone receptor-positive breast cancer. Based on this outcome, this investigators of this study revisit the benefits and harms of using risk-reducing medication when screening women for breast cancer. Although it is believed that suturing the use of these medications along with annual mammograms could reduce the risk of cancer, the medications are known to come with side effects. To minimize patient-risk exposure, it was found that using personalized data to assess high-risk cases was the best option for patients and providers when deciding disease management strategies.
Reference:
Jayasekera J, Zhao A, Schechter C, et al. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023;41(4):859-870. doi:10.1200/JCO.22.01342
Link: https://ascopubs.org/doi/full/10.1200/JCO.22.01342?role=tab
